top of page

When Local CAR-T Options Are Limited, There May Be Other Paths in China

We help you access leading hematology and CAR-T centers in China.

Confidential case review • We do not charge fees to help you apply. 

You may be exploring other options because:

I cannot get it locally 

I've exhausted standard treatments

My cancer has relapsed

I'm looking for a superior CAR-T option

A  COMPARISION

How China Compares on CAR-T

Complete remission rates:  ~40–67%  reported for relapsed/refractory lymphoma, and 60–80% for relapsed/refractory B-cell leukemia  comparable to global benchmarks for US products
 

Manufacturing speed: China now has one of the largest CAR-T therapy bases of CAR-T manufacturing anywhere,  a 9-day manufacturing turnaround is a life-saving metric compared with a 4-week manufacturing turnaround
 

High patient volume. Leading centers run high case volumes for CAR-T and hematology, supporting experienced clinical teams at a lower cost.

Why Choose Us: Physician-Led, Cross-Border Care, 10 Years of Experience, 3,000+ Cases Served

Dr. Sheena Liu, MD, PhD , an alumna of Columbia University College of Physician and Surgeon, Co-Founded Medebound HEALTH/ChinaCureLink with a Harvard Senior Physician(Dr. White) and another Columbia Doctor(Dr. Connolly) , in the City of New York.

Medebound Health, our parent company headquartered in New York, brings 10 years of experience in cross-border second opinions and medical concierge services, primarily connecting international patients with advanced care in the U.S
 

Building on that foundation, ChinaCureLink was established to help international families access advanced treatment options in China, including CAR-T therapy.
 

Our physician-founded and physician-led team includes a Harvard-trained physician, a former president of a New York medical college, and other distinguished academic medical leaders.

ChinaCureLink goes beyond medical coordination. Our team has deep relationships with China's medical network, cross-border healthcare expertise. We provide end-to-end support — from medical evaluation and hospital access to treatment coordination and on-the-ground assistance in China.

Harvard-Trained Physician 

Clinical leadership on our founding medical team

Former President, New York Medical College

Former President, New York Medical College

Nearly 10 Years of Cross-Border Care

Nearly 10 Years of Cross-Border Care

Similar Success Rates to Leading U.S. and EU CAR-T Programs at One-Third the Price

How to Access the BEST CAR-T PROGRAMS in China

Confidential case review • We do not charge fees to help you apply.

《Nature》2025: China Overtakes the US in Cancer Research Output

CHINA  CAR-T THERAPY

China is
One of the Most Active Nations in Next-Gen CAR-T Therapy

9 APPROVED:
5 CD 19, 3 BCMA, 1 CLAUDIN 18.2

Active Next-Generation Research Pipeline

Leading centers are advancing dual-target and allogeneic therapies, positioning China at the forefront of global CAR-T innovation.

Shorter Manufacturing Turnaround

 Leveraging high-volume production to deliver a faster manufacturing timeline compared to traditional global standards.

Lymphoma, Leukemia, Multiple Myeloma, Pediatric Cancers, and the World's First Solid Cancer

China has approved  9 CAR-T  therapies, howeveer there are ~470  ongoing trials in liver cancer, pancreatic cancer and other solid cancers and blood cancers. 

#1 Most Trusted Cross-Border Medical Service in Asia, 3000 patients served 10 years.

Talk to Us About Your Case

WHATSAPP our 24/7 on-duty medical staff. Jasmine is currently online and can reply within 5 minutes.

Our hospital matching and application are provided at no cost to you. We only require a modest fee for logistical support and on-ground coordination. If you do not use WhatsApp, please email us at support@medeboundhealth.com

HOW IT WORKS

ChinaCureLink: A Path to Treatment

For the last 10 years,  we have helped more than 3000 patients worldwide seeking advanced care in the US and in China

01

Free Advisory Call

We begin with a complimentary case review to assess your eligibility for CAR-T therapy in China.

02

Match 3 Top Hospitals

We identify and match you with the top 3 hematology hospitals in China specializing in CAR-T therapy.

03

Consult With Physician

You choose a hospital/physician. We set up a video consultation with Car T physician to review your eligibiity. 

04

Medical Visa 

We assist with the complex medical visa process, ensuring all documentation is in order before your travel.

05

Travel & Treatment

We assist with the complex medical visa process, ensuring all documentation is in order for your travel.

TOP 3 HOSPITALS: RANKED BY CHINA'S AUTHORITY HOSPITAL RATING SYSTEM BASED ON PATIENT VOLUME

What Does a Top 3 CAR-T Hospital in China Look Like?

On August 10, 2026, a 72-year-old female patient from Southeast Asia had a video consultation with LuDaoPei Hospital, one of the leading CAR-T centers in China.

High-Volume Hematology & CAR-T Center

One of China's largest hematology and cellular-therapy programs

  • #1 in China — 1,662 HSCT cases in 2025

  • #1 in China — Registered beds & transplant units

  • #1 in China — Hematology revenue

  • 3,000+ CAR-T clinical study cases

  • 385+ scientific publications, 2018–2025

  • 208+ presentations at ASH, EHA & EBMT

  • 270+ senior physicians across 4 specialized hospitals

  • 30+ countries represented among international patients

Why it matters: Exceptional treatment volume means extensive experience managing complex blood cancers, transplantation, CAR-T treatment and treatment-related complications.

Academic CAR-T & Clinical Research Center

A leading Chinese academic center for advanced cellular therapies

  • Major academic hematology and oncology center

  • Extensive CAR-T clinical research portfolio

  • Experience across multiple CAR-T targets and treatment strategies

  • Multidisciplinary teams for relapsed and refractory blood cancers

  • Integrated transplantation, cellular therapy, ICU and complication-management capabilities

  • Active participation in peer-reviewed clinical research

  • Experience evaluating complex patients after multiple prior therapies

  • Dedicated infrastructure for international patients

Why it matters: For patients who have exhausted standard treatment pathways, access to a research-intensive center may provide opportunities to explore trial strategies based on individual eligibility.

We Don't Match Patients by Hospital Ranking Alone.

The “best” CAR-T center depends on your diagnosis, previous treatments, disease status, CAR-T target, transplant history and clinical eligibility. Our team reviews your case and identifies appropriate leading centers before you decide whether traveling to China makes sense.

Confidential review • No obligation to travel

“Medebound/ChinaCureLink provided expert guidance for our family’s successful China treatment. They are a professional, trusted gateway to advanced care.”

A Case Study: Nine Years, One Leap: How Multiple Myeloma Led an Italian Woman to CAR-T Therapy in China

Timeline Summary

01. 4 weeks: Inquiry & Physician Consultation
02. 2 weeks: Hospital Matching & Review
03. 14 days: Treatment Duration in China
04. 100%: Complete Remission

9 years of relapsing multiple myeloma: Elena, a 64-year-old woman from Italy, entered a BCMA-CAR-T program in China after her disease became relapsed and refractory, meaning it had returned despite prior treatments and was no longer responding meaningfully to earlier drugs.

​

BCMA-targeted CAR-T therapy: Her own T-cells were collected, genetically modified to recognize BCMA (B-cell maturation antigen) on myeloma cells, multiplied in a laboratory, and returned as CAR-T cells designed to target those cancer cells.

​

September 16 to October 23, 2019: Elena arrived in China on September 16, 2019, underwent specialist review and trial assessment, and received her BCMA-CAR-T infusion on October 23, 2019 at a JCI-accredited Top 1 hematology hospital in the Beijing region.

​

The hospital’s 700th CAR-T trial patient: Elena was the 700th patient enrolled in the hospital’s CAR-T clinical trial program, following its 600th enrolment—a 7-year-old child with B-cell acute lymphoblastic leukemia—just 4 months earlier.

 

ChinaCureLink support for international families:  affiliated with Medebound HEALTH, a New York-headquartered medical concierge company with 10+ years of experience and 3,000+ patients served worldwide.

​

READ MORE CASES from CHINACURELINK

Two questions matter most when comparing countries:

What will it cost, and does it work effectively.

Why Families Choose China CART

Published data and hospital-level experience point to a consistent answer.

50-70%

Cost Savings

Significant reductions in treatment costs compared to traditional Western markets, achieved through high-volume manufacturing and hospital-set pricing models.

70%+

Match 3 Top Hospitals

High patient response rates across leading centers, with outcomes comparable to U.S. products based on published clinical data.

5000+

Consult With Physician

Leading centers perform over 1,000 CAR-T procedures annually, providing extensive clinical experience and high-volume clinical expertise.

Frequently asked questions

KESEHATAN Medebound

Operasi AS

Operasi Tiongkok

  Klik Disini

66 Jalan MiaoJing. #K471

Distrik MingHang, Shanghai
+86 400-616-2591

​

Disclaimer: Medebound HEALTH provides informational services only. Second opinions are provided solely for informational, educational, and reference purposes and are not intended to establish a physician-patient relationship. All patients have acknowledged this in writing.  All consultations are provided by independent U.S.-licensed physicians. This service is not provided, endorsed, or affiliated with any hospital as an institution.

  • X
  • Instagram
  • LinkedIn
  • Facebook

© 2022 oleh Medebound HEALTH

bottom of page